0001127602-23-006642.txt : 20230223
0001127602-23-006642.hdr.sgml : 20230223
20230223095427
ACCESSION NUMBER: 0001127602-23-006642
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230221
FILED AS OF DATE: 20230223
DATE AS OF CHANGE: 20230223
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kirchgraber Paul R
CENTRAL INDEX KEY: 0001791393
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-11353
FILM NUMBER: 23656939
MAIL ADDRESS:
STREET 1: 531 SOUTH SPRING STREET
CITY: BURLINGTON
STATE: NC
ZIP: 27215
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LABORATORY CORP OF AMERICA HOLDINGS
CENTRAL INDEX KEY: 0000920148
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 133757370
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 358 S MAIN ST
CITY: BURLINGTON
STATE: NC
ZIP: 27215
BUSINESS PHONE: 3362291127
MAIL ADDRESS:
STREET 1: 358 S MAIN ST
CITY: BURLINGTON
STATE: NC
ZIP: 27215
FORMER COMPANY:
FORMER CONFORMED NAME: NATIONAL HEALTH LABORATORIES HOLDINGS INC
DATE OF NAME CHANGE: 19940314
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2023-02-21
0000920148
LABORATORY CORP OF AMERICA HOLDINGS
LH
0001791393
Kirchgraber Paul R
531 SOUTH SPRING STREET
BURLINGTON
NC
27215
1
CEO, Covance Drug Development
Common Stock
2023-02-21
4
M
0
3000
182.51
A
17069
D
Common Stock
2023-02-21
4
S
0
8000
250.5844
D
9069
D
Non-qualified Stock Options
182.51
2023-02-21
4
M
0
3000
0
D
2021-02-04
2030-02-03
Common Stock
3000
4300
D
The price of $250.5844 per share represents a weighted average of sales prices ranging from $250.44 to $250.79 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a securityholder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan.
The option vested in three equal annual installments beginning on the date reflected in this column.
/s/ Sandra van der Vaart, Attorney-in-Fact for Paul R. Kirchgraber
2023-02-23